Net clinical benefit of anticoagulant therapy from a neurologist's perspective: A review

Cover Page

Cite item

Full Text

Abstract

In this article the concept of "net clinical benefit" (NCB) is considered in the context of stroke, the role of direct oral anticoagulants in secondary prevention of cardioembolic stroke and NCB from their prescription. Practical aspects of NCB evaluation from the neurologist's point of view are presented, taking into account such factors as stroke duration and severity, features of neurological deficit (severity of residual limitations, dysphagia, motor disorders and risk of falls), neuroimaging characteristics of stroke (focal size and hemorrhagic transformation) and concomitant neurological diseases (epilepsy and dementia). In all these situations, the use of oral anticoagulants has a significant clinical benefit, which justifies the inadmissibility of refusal to prescribe them.

About the authors

Aleksey A. Kulesh

Wagner Perm State Medical University

Author for correspondence.
Email: aleksey.kulesh@gmail.com
ORCID iD: 0000-0001-6061-8118

D. Sci. (Med.), Wagner Perm State Medical University

Russian Federation, Perm

References

  1. Seiffge DJ, Werring DJ, Paciaroni M, et al. Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation. Lancet Neurol. 2019;18(1):117-26. doi: 10.1016/S1474-4422(18)30356-9
  2. Hart RG, Coull BM, Hart D. Early recurrent embolism associated with nonvalvular atrial fibrillation: a retrospective study. Stroke. 1983;14(5):688-93. doi: 10.1161/01.str.14.5.688
  3. Muscari A, Faccioli L, Lega MV, et al. Predicting hemorrhagic transformation and its timing from maximum cerebral lesion diameter in nonlacunar ischemic strokes. Brain Behav. 2020;10(1):e01497. doi: 10.1002/brb3.1497
  4. Towse A. Net clinical benefit: the art and science of jointly estimating benefits and risks of medical treatment. Value Health. 2010;13(Suppl. 1):S30-2. doi: 10.1111/j.1524-4733.2010.00753.x
  5. Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost. 2012;107(3):584-9. doi: 10.1160/TH11-11-0784
  6. Renda G, di Nicola M, De Caterina R. Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials. Am J Med. 2015;128(9):1007-14.e2. doi: 10.1016/j.amjmed.2015.03.034
  7. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-62. doi: 10.1016/S0140-6736(13)62343-0
  8. Granger CB, Alexander JH, McMurray JJ, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. doi: 10.1056/NEJMoa1107039
  9. Diener HC, Hankey GJ, Easton JD, et al. Non-vitamin K oral anticoagulants for secondary stroke prevention in patients with atrial fibrillation. Eur Heart J Suppl. 2020;22(Suppl. I):I13-21. doi: 10.1093/eurheartj/suaa104
  10. Proietti M, Romanazzi I, Romiti GF, et al. Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis. Stroke. 2018;49(1):98-106. doi: 10.1161/STROKEAHA.117.018395
  11. Hsu JC, Hsieh CY, Yang YH, Lu CY. Net clinical benefit of oral anticoagulants: a multiple criteria decision analysis. PLoS One. 2015;10(4):e0124806. doi: 10.1371/journal.pone.0124806
  12. Ntaios G, Papavasileiou V, Makaritsis K, et al. Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis. Stroke. 2017;48(9):2494-503. doi: 10.1161/STROKEAHA.117.017549
  13. Patti G, Pecen L, Lucerna M, et al. Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation. Am J Med. 2019;132(6):749-57.e5. doi: 10.1016/j.amjmed.2018.12.036
  14. Polymeris AA, Macha K, Paciaroni M, et al; NOACISP-LONGTERM, Erlangen Registry, CROMIS-2, RAF, RAF-DOAC, SAMURAI-NVAF and Verona Registry Collaborators. Oral Anticoagulants in the Oldest Old with Recent Stroke and Atrial Fibrillation. Ann Neurol. 2022;91(1):78-88. doi: 10.1002/ana.26267
  15. Drogkaris S, Thomopoulos C, Kalos T, et al. Net clinical benefit of direct oral anticoagulants in atrial fibrillation patients with or without diabetes mellitus: A meta-analysis of outcome trials. Diabetes Res Clin Pract. 2021;182:109147. doi: 10.1016/j.diabres.2021.109147
  16. Amin A, Keshishian A, Dina O, et al. Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population. J Thromb Thrombolysis. 2019;48(2):240-9. doi: 10.1007/s11239-019-01838-5
  17. Shah SJ, Singer DE, Fang MC, et al. Net Clinical Benefit of Oral Anticoagulation Among Older Adults With Atrial Fibrillation. Circ Cardiovasc Qual Outcomes. 2019;12(11):e006212. doi: 10.1161/CIRCOUTCOMES.119.006212
  18. Esteve-Pastor MA, Rivera-Caravaca JM, Roldán V, et al. Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated "Real-World" in Patients With Atrial Fibrillation. Am J Cardiol. 2018;122(5):785-92. doi: 10.1016/j.amjcard.2018.05.012
  19. Zhang J, Wang X, Liu X, et al. Comparative effectiveness and safety of direct acting oral anticoagulants in nonvalvular atrial fibrillation for stroke prevention: a systematic review and meta-analysis. Eur J Epidemiol. 2021;36(8):793-812. doi: 10.1007/s10654-021-00751-7
  20. Paciaroni M, Agnelli G, Falocci N, et al. Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin-K Oral Anticoagulants (RAF-NOACs) Study. J Am Heart Assoc. 2017;6(12):e007034. doi: 10.1161/JAHA.117.007034
  21. Yoshimura S, Uchida K, Sakai N, et al. Safety of Early Administration of Apixaban on Clinical Outcomes in Patients with Acute Large Vessel Occlusion. Transl Stroke Res. 2021;12(2):266-74. doi: 10.1007/s12975-020-00839-4
  22. Alrohimi A, Buck B, Jickling G, et al. Early apixaban therapy after ischemic stroke in patients with atrial fibrillation. J Neurol. 2021;268(5):1837-46. doi: 10.1007/s00415-020-10335-2
  23. Кулеш А.А. Сложные вопросы ведения пациента с фибрилляцией предсердий с точки зрения невролога. Неврология, нейропсихиатрия, психосоматика. 2021;13(5):4-13 [Kulesh AA. Difficult issues in the management of patients with atrial fibrillation: a neurologist's point of view. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(5):4-13 (in Russian)]. doi: 10.14412/2074-2711-2021-5-4-13
  24. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):1609-78. doi: 10.1093/europace/euw295
  25. Kimura S, Toyoda K, Yoshimura S, et al; SAMURAI, RELAXED, RAF, RAF-NOAC, CROMIS-2, NOACISP LONGTERM, Erlangen Registry and Verona Registry Investigators. Practical "1-2-3-4-Day" Rule for Starting Direct Oral Anticoagulants After Ischemic Stroke With Atrial Fibrillation: Combined Hospital-Based Cohort Study. Stroke. 2022:STROKEAHA121036695. doi: 10.1161/STROKEAHA.121.036695
  26. Wilson D, Ambler G, Banerjee G, et al; Clinical relevance of Microbleeds in Stroke (CROMIS-2) collaborators. Early versus late anticoagulation for ischaemic stroke associated with atrial fibrillation: multicentre cohort study. J Neurol Neurosurg Psychiatry. 2019;90(3):320-5. doi: 10.1136/jnnp-2018-318890
  27. Кулеш А.А., Демин Д.А., Виноградов О.И. Патогенетические механизмы ишемического инсульта: от верификации до вторичной профилактики. Consilium Medicum. 2021;23(11):792-9 [Kulesh AA, Demin DA, Vinogradov OI. Pathogenetic mechanisms of ischemic stroke: from verification to secondary prevention. Consilium Medicum. 2021;23(11):792-9 (in Russian)]. doi: 10.26442/20751753.2021.11.201153
  28. Sacchetti DC, Furie KL, Yaghi S. Cardioembolic Stroke: Mechanisms and Therapeutics. Semin Neurol. 2017;37(3):326-38. doi: 10.1055/s-0037-1603465
  29. Кулеш А.А. Сложные вопросы внутривенной тромболитической терапии при ишемическом инсульте. Consilium Medicum. 2021;23(11):805-13 [Kulesh AA. Difficult questions of intravenous thrombolytic therapy in ischemic stroke. Consilium Medicum. 2021;23(11):805-13]. doi: 10.26442/20751753.2021.11.201143
  30. Zivanovic Z, Ostojic Z, Rajic S, et al. Outcome after intravenous thrombolysis in embolic stroke of undetermined source compared to cardioembolic stroke. Wien Klin Wochenschr. 2020;132(17-18):515-20. doi: 10.1007/s00508-020-01727-5
  31. Matusevicius M, Cooray C, Rand VM, et al. Stroke Etiology and Outcomes after Endovascular Thrombectomy: Results from the SITS Registry and a Meta-Analysis. J Stroke. 2021;23(3):388-400. doi: 10.5853/jos.2021.00850
  32. Meya L, Polymeris AA, Schaedelin S, et al. Oral Anticoagulants in Atrial Fibrillation Patients With Recent Stroke Who Are Dependent on the Daily Help of Others. Stroke. 2021;52(11):3472-81. doi: 10.1161/STROKEAHA.120.033862
  33. Cohen DL, Roffe C, Beavan J, et al. Post-stroke dysphagia: A review and design considerations for future trials. Int J Stroke. 2016;11(4):399-411. doi: 10.1177/1747493016639057
  34. Jones CA, Colletti CM, Ding MC. Post-stroke Dysphagia: Recent Insights and Unanswered Questions. Curr Neurol Neurosci Rep. 2020;20(12):61. doi: 10.1007/s11910-020-01081-z
  35. Zhang L, Tang X, Wang C, et al. Predictive Model of Dysphagia and Brain Lesion-Symptom Mapping in Acute Ischemic Stroke. Front Aging Neurosci. 2021;13:753364. doi: 10.3389/fnagi.2021.753364
  36. Dziewas R, Michou E, Trapl-Grundschober M, et al. European Stroke Organisation and European Society for Swallowing Disorders guideline for the diagnosis and treatment of post-stroke dysphagia. Eur Stroke J. 2021;6(3):LXXXIX-CXV. doi: 10.1177/23969873211039721
  37. Vannucchi V, Moroni F, Grifoni E, et al. Management of oral anticoagulation in very old patients with non valvular atrial fibrillation related acute ischemic stroke. J Thromb Thrombolysis. 2020;49(1):86-93. doi: 10.1007/s11239-019-01972-0
  38. Odell K, Costello J. Safety of Apixaban Administered via Nasogastric Tube. Cardiology. 2019;142(1):39. doi: 10.1159/000495577
  39. Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021;23(10):1612-76. doi: 10.1093/europace/euab065
  40. Teasell R, Salbach NM, Foley N, et al. Canadian Stroke Best Practice Recommendations: Rehabilitation, Recovery, and Community Participation following Stroke. Part One: Rehabilitation and Recovery Following Stroke; 6th Edition Update 2019. Int J Stroke. 2020;15(7):763-88. doi: 10.1177/1747493019897843
  41. D'Amario D, Galli M, Cappannoli L, et al. Oral anticoagulants in fragile patients with percutaneous endoscopic gastrostomy and atrial fibrillation: the ORIGAMI pilot investigation. Minerva Cardiol Angiol. 2022. doi: 10.23736/S2724-5683.21.05903-2
  42. Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999;159(7):677-85. doi: 10.1001/archinte.159.7.677
  43. Rao MP, Vinereanu D, Wojdyla DM, et al. Clinical outcomes and history of fall in patients with atrial fibrillation treated with oral anticoagulation: insights from the ARISTOTLE trial. Am J Med. 2018;131(3):269-75e2. doi: 10.1016/j.amjmed.2017.10.036
  44. Winstein CJ, Stein J, Arena R, et al; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Quality of Care and Outcomes Research. Guidelines for Adult Stroke Rehabilitation and Recovery: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2016;47(6):e98-169. doi: 10.1161/STR.0000000000000098
  45. Jung J-M, Kwon SU, Lee JH, Kang D-W. Difference in infarct volume and patterns between cardioembolism and internal carotid artery disease: focus on the degree of cardioembolic risk and carotid stenosis. Cerebrovasc Dis. 2010;29(5):490-6. doi: 10.1159/000297965
  46. Daneshvari NO, Johansen MC. Associations between cerebral magnetic resonance imaging infarct volume and acute ischemic stroke etiology. PLoS One. 2021;16(8):e0256458. doi: 10.1371/journal.pone.0256458
  47. Paciaroni M, Agnelli G, Corea F, et al. Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke. 2008;39(8):2249-56. doi: 10.1161/STROKEAHA.107.510321
  48. Thomas SE, Plumber N, Venkatapathappa P, Gorantla V. A Review of Risk Factors and Predictors for Hemorrhagic Transformation in Patients with Acute Ischemic Stroke. Int J Vasc Med. 2021;2021:4244267. doi: 10.1155/2021/4244267
  49. Vaclavik D, Vilionskis A, Jatuzis D, et al. Clinical outcome of cardioembolic stroke treated by intravenous thrombolysis. Acta Neurol Scand. 2018;137(3):347-55. doi: 10.1111/ane.12880
  50. Kam W, Holmes DN, Hernandez AF, et al. Association of Recent Use of Non-Vitamin K Antagonist Oral Anticoagulants With Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Treated With Alteplase. JAMA. 2022;327(8):760-71.
  51. Hong JM, Kim DS, Kim M. Hemorrhagic Transformation After Ischemic Stroke: Mechanisms and Management. Front Neurol. 2021;12:703258. doi: 10.3389/fneur.2021.703258
  52. Sandset EC, Anderson CS, Bath PM, et al. European Stroke Organisation (ESO) guidelines on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage. Eur Stroke J. 2021;6(2):II. doi: 10.1177/23969873211026998
  53. Anderson CS, Huang Y, Lindley RI, et al; ENCHANTED Investigators and Coordinators. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial. Lancet. 2019;393(10174):877-88. doi: 10.1016/S0140-6736(19)30038-8
  54. Paciaroni M, Bandini F, Agnelli G, et al. Hemorrhagic Transformation in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Time to Initiation of Oral Anticoagulant Therapy and Outcomes. J Am Heart Assoc. 2018;7(22):e010133. doi: 10.1161/JAHA.118.010133
  55. Zou S, Wu X, Zhu B, et al. The pooled incidence of post-stroke seizure in 102 008 patients. Top Stroke Rehabil. 2015;22(6):460-7. doi: 10.1179/1074935715Z.00000000062
  56. Beghi E, D'Alessandro R, Beretta S, et al; Epistroke Group. Incidence and predictors of acute symptomatic seizures after stroke. Neurology. 2011;77(20):1785-93. doi: 10.1212/WNL.0b013e3182364878
  57. Stefanidou M, Das RR, Beiser AS, et al. Incidence of seizures following initial ischemic stroke in a community-based cohort: The Framingham Heart Study. Seizure. 2017;47:105-10. doi: 10.1016/j.seizure.2017.03.009
  58. Holtkamp M, Beghi E, Benninger F, et al; European Stroke Organisation. European Stroke Organisation guidelines for the management of post-stroke seizures and epilepsy. Eur Stroke J. 2017;2(2):103-15. doi: 10.1177/2396987317705536
  59. Galovic M, Döhler N, Erdélyi-Canavese B, et al. Prediction of late seizures after ischaemic stroke with a novel prognostic model (the SeLECT score): a multivariable prediction model development and validation study. Lancet Neurol. 2018;17(2):143-52. doi: 10.1016/S1474-4422(17)30404-0
  60. Leung T, Leung H, Soo YO, et al. The prognosis of acute symptomatic seizures after ischaemic stroke. J Neurol Neurosurg Psychiatry. 2017;88(1):86-94. doi: 10.1136/jnnp-2015-311849
  61. Steffel J, Collins R, Antz M, et al; External reviewers. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021;23(10):1612-76. doi: 10.1093/europace/euab065
  62. Stöllberger C, Finsterer J. Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs. Epilepsy Res. 2016;126:98-101. doi: 10.1016/j.eplepsyres.2016.06.003
  63. Zöllner JP, Schmitt FC, Rosenow F, et al. Seizures and epilepsy in patients with ischaemic stroke. Neurol Res Pract. 2021;3(1):63. doi: 10.1186/s42466-021-00161-w
  64. Banerjee A, Benedetto V, Gichuru P, et al. Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study. Heart. 2020;106(2):119-26. doi: 10.1136/heartjnl-2019-315307
  65. Ozaki AF, Choi AS, Le QT, et al. Real-World Adherence and Persistence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Circ Cardiovasc Qual Outcomes. 2020;13(3):e005969. doi: 10.1161/CIRCOUTCOMES.119.005969
  66. Mainbourg S, Cucherat M, Provencher S, et al; META-EMBOL group. Twice- or Once-Daily Dosing of Direct Oral Anticoagulants, a systematic review and meta-analysis. Thromb Res. 2021;197:24-32. doi: 10.1016/j.thromres.2020.10.011
  67. Lee ZX, Ang E, Lim XT, Arain SJ. Association of Risk of Dementia With Direct Oral Anticoagulants Versus Warfarin Use in Patients With Non-valvular Atrial Fibrillation: A Systematic Review and Meta-analysis. J Cardiovasc Pharmacol. 2021;77(1):22-31. doi: 10.1097/FJC.0000000000000925
  68. Ray WA, Chung CP, Stein CM, et al. Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation. JAMA. 2021;326(23):2395-404. doi: 10.1001/jama.2021.21222

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1

Download (131KB)
Indexing metadata

Copyright (c) 2022 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies